4-(cyclopropyloxy)-N-[5-(2-methylphenyl)-1,3,4-thiadiazol-2-yl]-3-({[1-(4-methylpiperazin-1-yl)cyclopropyl]carbonyl}amino)benzamide,

4-(difluoromethoxy)-N-[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]-3-{[(4-methylpiperazin-1-yl)acetyl]amino}benzamide,

3-{[(4-cyclopropylpiperazin-1-yl)acetyl]amino}-4-(difluoromethoxy)-N-[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide, and

4-(difluoromethoxy)-N-[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]-3-[(morpholin-4-ylacetyl)amino]benzamide;

or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same.

3. A pharmaceutical composition comprising a compound of general formula (I), or a stereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 or 2, and a pharmaceutically acceptable diluent or carrier.

4. A pharmaceutical combination comprising :

- one or more first active ingredients selected from a compound of general formula (I) according to any of claims 1 or 2, and
- one or more second active ingredients selected from chemotherapeutic anti cancer agents.

5. A compound of general formula (I), or a stereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 or 2, for use in the prophylaxis or treatment of a disease.

6. Use of a compound of general formula (I), or a stereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 or 2, in the manufacture of a medicament for the treatment of cardiovascular diseases, chronic kidney disease, carcinomas and cancers.